Separately, StockNews.com initiated coverage on shares of Titan Pharmaceuticals in a research report on Saturday, May 21st. They set a hold rating for the company.
Shares of Titan Pharmaceuticals stock opened at $0.40 on Thursday. The company has a fifty day moving average price of $0.74 and a 200 day moving average price of $1.01. Titan Pharmaceuticals has a twelve month low of $0.35 and a twelve month high of $3.10.
About Titan Pharmaceuticals (Get Rating)
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union.
- Get a free copy of the StockNews.com research report on Titan Pharmaceuticals (TTNP)
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
- Genesco Pops On Earnings But Don’t Expect A Rally
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.